[
  {
    "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
    "bbox": [
      458,
      97,
      875,
      107
    ],
    "label": 1,
    "category": "Document Name"
  },
  {
    "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
    "bbox": [
      179,
      113,
      1000,
      125
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
    "bbox": [
      113,
      145,
      1000,
      157
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
    "bbox": [
      179,
      113,
      1000,
      125
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
    "bbox": [
      113,
      145,
      1000,
      157
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
    "bbox": [
      179,
      113,
      1000,
      125
    ],
    "label": 3,
    "category": "Agreement Date"
  },
  {
    "text": "Exhibit 10.54",
    "bbox": [
      1000,
      81,
      1000,
      91
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
    "bbox": [
      458,
      97,
      875,
      107
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
    "bbox": [
      179,
      113,
      1000,
      125
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
    "bbox": [
      113,
      145,
      1000,
      157
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
    "bbox": [
      113,
      161,
      725,
      173
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
    "bbox": [
      179,
      176,
      1000,
      189
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "controls; and",
    "bbox": [
      112,
      193,
      212,
      204
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
    "bbox": [
      179,
      208,
      1000,
      221
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
    "bbox": [
      179,
      224,
      1000,
      237
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "products.",
    "bbox": [
      112,
      242,
      182,
      253
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
    "bbox": [
      178,
      257,
      1000,
      269
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.",
    "bbox": [
      110,
      272,
      128,
      284
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Definitions",
    "bbox": [
      179,
      272,
      266,
      284
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.1.",
    "bbox": [
      144,
      288,
      173,
      300
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
    "bbox": [
      214,
      288,
      1000,
      302
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
    "bbox": [
      213,
      305,
      1000,
      317
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
    "bbox": [
      213,
      320,
      1000,
      333
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.2.",
    "bbox": [
      143,
      335,
      173,
      349
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
    "bbox": [
      214,
      337,
      1000,
      349
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
    "bbox": [
      213,
      354,
      1000,
      364
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
    "bbox": [
      212,
      369,
      1000,
      381
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
    "bbox": [
      212,
      384,
      1000,
      397
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
    "bbox": [
      214,
      400,
      1000,
      412
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
    "bbox": [
      214,
      417,
      1000,
      429
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.3.",
    "bbox": [
      144,
      432,
      172,
      444
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
    "bbox": [
      214,
      433,
      1000,
      445
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
    "bbox": [
      213,
      449,
      1000,
      461
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "such additional geographies.",
    "bbox": [
      213,
      465,
      430,
      477
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.4.",
    "bbox": [
      143,
      480,
      172,
      492
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Available Margin is defined on Exhibit A.",
    "bbox": [
      216,
      482,
      519,
      491
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.5.",
    "bbox": [
      144,
      496,
      173,
      508
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
    "bbox": [
      212,
      496,
      1000,
      509
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "mutual agreement of Qualigen and Sekisui..",
    "bbox": [
      213,
      513,
      532,
      524
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.6.",
    "bbox": [
      143,
      528,
      172,
      541
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "COGS is defined on Exhibit A..",
    "bbox": [
      214,
      529,
      437,
      540
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Exhibit 10.54",
    "bbox": [
      1000,
      81,
      1000,
      91
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
    "bbox": [
      458,
      97,
      875,
      107
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
    "bbox": [
      179,
      113,
      1000,
      125
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
    "bbox": [
      113,
      145,
      1000,
      157
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
    "bbox": [
      113,
      161,
      725,
      173
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
    "bbox": [
      179,
      176,
      1000,
      189
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "controls; and",
    "bbox": [
      112,
      193,
      212,
      204
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
    "bbox": [
      179,
      208,
      1000,
      221
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
    "bbox": [
      179,
      224,
      1000,
      237
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "products.",
    "bbox": [
      112,
      242,
      182,
      253
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
    "bbox": [
      178,
      257,
      1000,
      269
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.",
    "bbox": [
      110,
      272,
      128,
      284
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Definitions",
    "bbox": [
      179,
      272,
      266,
      284
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.1.",
    "bbox": [
      144,
      288,
      173,
      300
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
    "bbox": [
      214,
      288,
      1000,
      302
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
    "bbox": [
      213,
      305,
      1000,
      317
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
    "bbox": [
      213,
      320,
      1000,
      333
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.2.",
    "bbox": [
      143,
      335,
      173,
      349
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
    "bbox": [
      214,
      337,
      1000,
      349
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
    "bbox": [
      213,
      354,
      1000,
      364
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
    "bbox": [
      212,
      369,
      1000,
      381
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
    "bbox": [
      212,
      384,
      1000,
      397
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
    "bbox": [
      214,
      400,
      1000,
      412
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
    "bbox": [
      214,
      417,
      1000,
      429
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.3.",
    "bbox": [
      144,
      432,
      172,
      444
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
    "bbox": [
      214,
      433,
      1000,
      445
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
    "bbox": [
      213,
      449,
      1000,
      461
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "such additional geographies.",
    "bbox": [
      213,
      465,
      430,
      477
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.4.",
    "bbox": [
      143,
      480,
      172,
      492
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Available Margin is defined on Exhibit A.",
    "bbox": [
      216,
      482,
      519,
      491
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.5.",
    "bbox": [
      144,
      496,
      173,
      508
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
    "bbox": [
      212,
      496,
      1000,
      509
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "mutual agreement of Qualigen and Sekisui..",
    "bbox": [
      213,
      513,
      532,
      524
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.6.",
    "bbox": [
      143,
      528,
      172,
      541
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "COGS is defined on Exhibit A..",
    "bbox": [
      214,
      529,
      437,
      540
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Exhibit 10.54",
    "bbox": [
      1000,
      81,
      1000,
      91
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
    "bbox": [
      458,
      97,
      875,
      107
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
    "bbox": [
      179,
      113,
      1000,
      125
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
    "bbox": [
      113,
      145,
      1000,
      157
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
    "bbox": [
      113,
      161,
      725,
      173
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
    "bbox": [
      179,
      176,
      1000,
      189
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "controls; and",
    "bbox": [
      112,
      193,
      212,
      204
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
    "bbox": [
      179,
      208,
      1000,
      221
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
    "bbox": [
      179,
      224,
      1000,
      237
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "products.",
    "bbox": [
      112,
      242,
      182,
      253
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
    "bbox": [
      178,
      257,
      1000,
      269
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.",
    "bbox": [
      110,
      272,
      128,
      284
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Definitions",
    "bbox": [
      179,
      272,
      266,
      284
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.1.",
    "bbox": [
      144,
      288,
      173,
      300
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
    "bbox": [
      214,
      288,
      1000,
      302
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
    "bbox": [
      213,
      305,
      1000,
      317
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
    "bbox": [
      213,
      320,
      1000,
      333
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.2.",
    "bbox": [
      143,
      335,
      173,
      349
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
    "bbox": [
      214,
      337,
      1000,
      349
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
    "bbox": [
      213,
      354,
      1000,
      364
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
    "bbox": [
      212,
      369,
      1000,
      381
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
    "bbox": [
      212,
      384,
      1000,
      397
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
    "bbox": [
      214,
      400,
      1000,
      412
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
    "bbox": [
      214,
      417,
      1000,
      429
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.3.",
    "bbox": [
      144,
      432,
      172,
      444
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
    "bbox": [
      214,
      433,
      1000,
      445
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
    "bbox": [
      213,
      449,
      1000,
      461
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "such additional geographies.",
    "bbox": [
      213,
      465,
      430,
      477
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.4.",
    "bbox": [
      143,
      480,
      172,
      492
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Available Margin is defined on Exhibit A.",
    "bbox": [
      216,
      482,
      519,
      491
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.5.",
    "bbox": [
      144,
      496,
      173,
      508
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
    "bbox": [
      212,
      496,
      1000,
      509
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "mutual agreement of Qualigen and Sekisui..",
    "bbox": [
      213,
      513,
      532,
      524
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.6.",
    "bbox": [
      143,
      528,
      172,
      541
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "COGS is defined on Exhibit A..",
    "bbox": [
      214,
      529,
      437,
      540
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Exhibit 10.54",
    "bbox": [
      1000,
      81,
      1000,
      91
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
    "bbox": [
      458,
      97,
      875,
      107
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
    "bbox": [
      179,
      113,
      1000,
      125
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
    "bbox": [
      113,
      145,
      1000,
      157
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
    "bbox": [
      113,
      161,
      725,
      173
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
    "bbox": [
      179,
      176,
      1000,
      189
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "controls; and",
    "bbox": [
      112,
      193,
      212,
      204
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
    "bbox": [
      179,
      208,
      1000,
      221
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
    "bbox": [
      179,
      224,
      1000,
      237
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "products.",
    "bbox": [
      112,
      242,
      182,
      253
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
    "bbox": [
      178,
      257,
      1000,
      269
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.",
    "bbox": [
      110,
      272,
      128,
      284
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Definitions",
    "bbox": [
      179,
      272,
      266,
      284
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.1.",
    "bbox": [
      144,
      288,
      173,
      300
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
    "bbox": [
      214,
      288,
      1000,
      302
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
    "bbox": [
      213,
      305,
      1000,
      317
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
    "bbox": [
      213,
      320,
      1000,
      333
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.2.",
    "bbox": [
      143,
      335,
      173,
      349
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
    "bbox": [
      214,
      337,
      1000,
      349
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
    "bbox": [
      213,
      354,
      1000,
      364
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
    "bbox": [
      212,
      369,
      1000,
      381
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
    "bbox": [
      212,
      384,
      1000,
      397
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
    "bbox": [
      214,
      400,
      1000,
      412
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
    "bbox": [
      214,
      417,
      1000,
      429
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.3.",
    "bbox": [
      144,
      432,
      172,
      444
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
    "bbox": [
      214,
      433,
      1000,
      445
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
    "bbox": [
      213,
      449,
      1000,
      461
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "such additional geographies.",
    "bbox": [
      213,
      465,
      430,
      477
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.4.",
    "bbox": [
      143,
      480,
      172,
      492
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Available Margin is defined on Exhibit A.",
    "bbox": [
      216,
      482,
      519,
      491
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.5.",
    "bbox": [
      144,
      496,
      173,
      508
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
    "bbox": [
      212,
      496,
      1000,
      509
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "mutual agreement of Qualigen and Sekisui..",
    "bbox": [
      213,
      513,
      532,
      524
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.6.",
    "bbox": [
      143,
      528,
      172,
      541
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "COGS is defined on Exhibit A..",
    "bbox": [
      214,
      529,
      437,
      540
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Exhibit 10.54",
    "bbox": [
      1000,
      81,
      1000,
      91
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
    "bbox": [
      458,
      97,
      875,
      107
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
    "bbox": [
      179,
      113,
      1000,
      125
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
    "bbox": [
      113,
      145,
      1000,
      157
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
    "bbox": [
      113,
      161,
      725,
      173
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
    "bbox": [
      179,
      176,
      1000,
      189
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "controls; and",
    "bbox": [
      112,
      193,
      212,
      204
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
    "bbox": [
      179,
      208,
      1000,
      221
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
    "bbox": [
      179,
      224,
      1000,
      237
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "products.",
    "bbox": [
      112,
      242,
      182,
      253
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
    "bbox": [
      178,
      257,
      1000,
      269
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.",
    "bbox": [
      110,
      272,
      128,
      284
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Definitions",
    "bbox": [
      179,
      272,
      266,
      284
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.1.",
    "bbox": [
      144,
      288,
      173,
      300
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
    "bbox": [
      214,
      288,
      1000,
      302
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
    "bbox": [
      213,
      305,
      1000,
      317
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
    "bbox": [
      213,
      320,
      1000,
      333
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.2.",
    "bbox": [
      143,
      335,
      173,
      349
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
    "bbox": [
      214,
      337,
      1000,
      349
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
    "bbox": [
      213,
      354,
      1000,
      364
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
    "bbox": [
      212,
      369,
      1000,
      381
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
    "bbox": [
      212,
      384,
      1000,
      397
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
    "bbox": [
      214,
      400,
      1000,
      412
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
    "bbox": [
      214,
      417,
      1000,
      429
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.3.",
    "bbox": [
      144,
      432,
      172,
      444
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
    "bbox": [
      214,
      433,
      1000,
      445
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
    "bbox": [
      213,
      449,
      1000,
      461
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "such additional geographies.",
    "bbox": [
      213,
      465,
      430,
      477
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.4.",
    "bbox": [
      143,
      480,
      172,
      492
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Available Margin is defined on Exhibit A.",
    "bbox": [
      216,
      482,
      519,
      491
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.5.",
    "bbox": [
      144,
      496,
      173,
      508
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
    "bbox": [
      212,
      496,
      1000,
      509
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "mutual agreement of Qualigen and Sekisui..",
    "bbox": [
      213,
      513,
      532,
      524
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "1.6.",
    "bbox": [
      143,
      528,
      172,
      541
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "COGS is defined on Exhibit A..",
    "bbox": [
      214,
      529,
      437,
      540
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 12,
    "category": "No-Solicit Of Customers"
  },
  {
    "text": "Exhibit 10.54",
    "bbox": [
      1000,
      81,
      1000,
      91
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
    "bbox": [
      458,
      97,
      875,
      107
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
    "bbox": [
      179,
      113,
      1000,
      125
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
    "bbox": [
      113,
      145,
      1000,
      157
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
    "bbox": [
      113,
      161,
      725,
      173
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
    "bbox": [
      179,
      176,
      1000,
      189
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "controls; and",
    "bbox": [
      112,
      193,
      212,
      204
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
    "bbox": [
      179,
      208,
      1000,
      221
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
    "bbox": [
      179,
      224,
      1000,
      237
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "products.",
    "bbox": [
      112,
      242,
      182,
      253
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
    "bbox": [
      178,
      257,
      1000,
      269
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.",
    "bbox": [
      110,
      272,
      128,
      284
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Definitions",
    "bbox": [
      179,
      272,
      266,
      284
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.",
    "bbox": [
      144,
      288,
      173,
      300
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
    "bbox": [
      214,
      288,
      1000,
      302
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
    "bbox": [
      213,
      305,
      1000,
      317
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
    "bbox": [
      213,
      320,
      1000,
      333
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.2.",
    "bbox": [
      143,
      335,
      173,
      349
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
    "bbox": [
      214,
      337,
      1000,
      349
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
    "bbox": [
      213,
      354,
      1000,
      364
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
    "bbox": [
      212,
      369,
      1000,
      381
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
    "bbox": [
      212,
      384,
      1000,
      397
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
    "bbox": [
      214,
      400,
      1000,
      412
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
    "bbox": [
      214,
      417,
      1000,
      429
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.3.",
    "bbox": [
      144,
      432,
      172,
      444
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
    "bbox": [
      214,
      433,
      1000,
      445
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
    "bbox": [
      213,
      449,
      1000,
      461
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "such additional geographies.",
    "bbox": [
      213,
      465,
      430,
      477
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.4.",
    "bbox": [
      143,
      480,
      172,
      492
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Available Margin is defined on Exhibit A.",
    "bbox": [
      216,
      482,
      519,
      491
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.5.",
    "bbox": [
      144,
      496,
      173,
      508
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
    "bbox": [
      212,
      496,
      1000,
      509
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "mutual agreement of Qualigen and Sekisui..",
    "bbox": [
      213,
      513,
      532,
      524
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.6.",
    "bbox": [
      143,
      528,
      172,
      541
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "COGS is defined on Exhibit A..",
    "bbox": [
      214,
      529,
      437,
      540
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Exhibit 10.54",
    "bbox": [
      1000,
      81,
      1000,
      91
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
    "bbox": [
      458,
      97,
      875,
      107
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
    "bbox": [
      179,
      113,
      1000,
      125
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
    "bbox": [
      113,
      145,
      1000,
      157
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
    "bbox": [
      113,
      161,
      725,
      173
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
    "bbox": [
      179,
      176,
      1000,
      189
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "controls; and",
    "bbox": [
      112,
      193,
      212,
      204
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
    "bbox": [
      179,
      208,
      1000,
      221
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
    "bbox": [
      179,
      224,
      1000,
      237
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "products.",
    "bbox": [
      112,
      242,
      182,
      253
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
    "bbox": [
      178,
      257,
      1000,
      269
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.",
    "bbox": [
      110,
      272,
      128,
      284
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Definitions",
    "bbox": [
      179,
      272,
      266,
      284
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.",
    "bbox": [
      144,
      288,
      173,
      300
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
    "bbox": [
      214,
      288,
      1000,
      302
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
    "bbox": [
      213,
      305,
      1000,
      317
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
    "bbox": [
      213,
      320,
      1000,
      333
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.2.",
    "bbox": [
      143,
      335,
      173,
      349
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
    "bbox": [
      214,
      337,
      1000,
      349
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
    "bbox": [
      213,
      354,
      1000,
      364
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
    "bbox": [
      212,
      369,
      1000,
      381
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
    "bbox": [
      212,
      384,
      1000,
      397
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
    "bbox": [
      214,
      400,
      1000,
      412
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
    "bbox": [
      214,
      417,
      1000,
      429
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.3.",
    "bbox": [
      144,
      432,
      172,
      444
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
    "bbox": [
      214,
      433,
      1000,
      445
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
    "bbox": [
      213,
      449,
      1000,
      461
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "such additional geographies.",
    "bbox": [
      213,
      465,
      430,
      477
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.4.",
    "bbox": [
      143,
      480,
      172,
      492
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Available Margin is defined on Exhibit A.",
    "bbox": [
      216,
      482,
      519,
      491
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.5.",
    "bbox": [
      144,
      496,
      173,
      508
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
    "bbox": [
      212,
      496,
      1000,
      509
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "mutual agreement of Qualigen and Sekisui..",
    "bbox": [
      213,
      513,
      532,
      524
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.6.",
    "bbox": [
      143,
      528,
      172,
      541
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "COGS is defined on Exhibit A..",
    "bbox": [
      214,
      529,
      437,
      540
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Exhibit 10.54",
    "bbox": [
      1000,
      81,
      1000,
      91
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
    "bbox": [
      458,
      97,
      875,
      107
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
    "bbox": [
      179,
      113,
      1000,
      125
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
    "bbox": [
      111,
      128,
      1000,
      141
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
    "bbox": [
      113,
      145,
      1000,
      157
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
    "bbox": [
      113,
      161,
      725,
      173
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
    "bbox": [
      179,
      176,
      1000,
      189
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "controls; and",
    "bbox": [
      112,
      193,
      212,
      204
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
    "bbox": [
      179,
      208,
      1000,
      221
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
    "bbox": [
      179,
      224,
      1000,
      237
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "products.",
    "bbox": [
      112,
      242,
      182,
      253
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
    "bbox": [
      178,
      257,
      1000,
      269
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.",
    "bbox": [
      110,
      272,
      128,
      284
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Definitions",
    "bbox": [
      179,
      272,
      266,
      284
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.",
    "bbox": [
      144,
      288,
      173,
      300
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
    "bbox": [
      214,
      288,
      1000,
      302
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
    "bbox": [
      213,
      305,
      1000,
      317
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
    "bbox": [
      213,
      320,
      1000,
      333
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.2.",
    "bbox": [
      143,
      335,
      173,
      349
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
    "bbox": [
      214,
      337,
      1000,
      349
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
    "bbox": [
      213,
      354,
      1000,
      364
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
    "bbox": [
      212,
      369,
      1000,
      381
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
    "bbox": [
      212,
      384,
      1000,
      397
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
    "bbox": [
      214,
      400,
      1000,
      412
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
    "bbox": [
      214,
      417,
      1000,
      429
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.3.",
    "bbox": [
      144,
      432,
      172,
      444
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
    "bbox": [
      214,
      433,
      1000,
      445
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
    "bbox": [
      213,
      449,
      1000,
      461
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "such additional geographies.",
    "bbox": [
      213,
      465,
      430,
      477
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.4.",
    "bbox": [
      143,
      480,
      172,
      492
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Available Margin is defined on Exhibit A.",
    "bbox": [
      216,
      482,
      519,
      491
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.5.",
    "bbox": [
      144,
      496,
      173,
      508
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
    "bbox": [
      212,
      496,
      1000,
      509
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "mutual agreement of Qualigen and Sekisui..",
    "bbox": [
      213,
      513,
      532,
      524
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.6.",
    "bbox": [
      143,
      528,
      172,
      541
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "COGS is defined on Exhibit A..",
    "bbox": [
      214,
      529,
      437,
      540
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 38,
    "category": "Insurance"
  }
]